Elgan Pharma is moving forward with a confirmatory Phase III study of ELGN-GI, an enteral insulin formulation for the treatment of intestinal malabsorption in preterm infants, a condition that can lead to other complications and life-threatening events. The company announced plans on 2 March to initiate a confirmatory Phase III trial studying ELGN-GI in premature infants, following the publication of positive Phase III trial results in JAMA Pediatrics on 28 February.
Company founder and CEO Miki Olshansky believes ELGN-GI could be a multibillion-dollar commercial opportunity given how common premature births are,...